Morgan Stanley Reduces PT on Jazz Pharmaceuticals plc (JAZZ) from $166 to $165; Maintains 'Buy' Rating

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is included in our list of the 10 Most Undervalued Foreign Stocks to Buy According to Analysts.

Despite early-year challenges, Jazz Pharmaceuticals plc (NASDAQ:JAZZ) remains a ‘Buy’.

On July 22, 2025, Morgan Stanley maintained its ‘Buy’ rating on JAZZ. However, the analyst lowered its price target slightly from $166 to $165. The analyst attributes its bullish stance to its expectation that the company will bounce back in the second half of the year, following a 10% miss in its Q1 net product sales. This expectation is driven by an extra shipping week in the Oncology segment, stronger demand for Rylaze due to pediatric protocol shifts, and seasonal strength in sleep disorder medication.

Meanwhile, Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is expected to experience major clinical developments with HERIZON-GEA-01 data and the anticipated dordaviprone FDA decision. Furthermore, the upcoming leadership change boosts optimism. Looking ahead, the analyst’s oncology revenue estimate exceeds the street’s estimates.

On the other hand, Wells Fargo reinforced this outlook, maintaining a ‘Buy’ rating on July 18 with a price target of $170.

Operating in the United States, Europe, and other global markets, Jazz Pharmaceuticals plc (NASDAQ:JAZZ) develops and commercializes pharmaceutical products. It remains on our list of the most undervalued stocks.

While we acknowledge the potential of JAZZ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 14 Cheap Transportation Stocks to Buy According to Analysts and 10 Cheap Lithium Stocks to Buy According to Hedge Funds.

Disclosure: None.